Table 1.

Interactions of reovirus and chemotherapy

A. Synergistic interaction of reovirus and chemotherapy on B16.F10
ChemotherapeuticED50ED70ED95
Cisplatin0.42 ± 0.030.30 ± 0.020.24 ± 0.01
DTIC0.80 ± 0.100.66 ± 0.080.56 ± 0.10
Gemcitabine0.47 ± 0.090.47 ± 0.070.48 ± 0.04
Paclitaxel0.44 ± 0.090.38 ± 0.110.35 ± 0.14
Carboplatin0.62 ± 0.010.56 ± 0.020.50 ± 0.03
B. Interaction of reovirus and cisplatin on other melanoma cell lines
Cell lineED50ED70ED95
K17350.92 ± 0.020.78 ± 0.010.57 ± 0.01
Mel 8881.37 ± 0.021.02 ± 0.030.77 ± 0.04
SM0.84 ± 0.020.54 ± 0.010.36 ± 0.01
OM0.88 ± 0.040.67 ± 0.040.52 ± 0.03
C. Presence of live virus in tumor tissue and selected organs of reovirus-treated mice
No. animals positive for virus by plaque assay
TumorLiverLungsHeart
Reovirus6/61/60/61/6
Combination3/64/60/60/6
Cisplatin0/30/30/30/3
Control0/30/30/30/3

NOTE: Data are presented as CI values ± SE at the effective dose indicated. Median survival (days): reovirus, 12; combination, 17; cisplatin, 8; control, 6.